PUBLISHER: DelveInsight | PRODUCT CODE: 1377966
PUBLISHER: DelveInsight | PRODUCT CODE: 1377966
“"Bertilimumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about bertilimumab for bullous pemphigoid in the seven major markets. A detailed picture of the bertilimumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the bertilimumab for bullous pemphigoid. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the bertilimumab market forecast analysis for bullous pemphigoid in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bullous pemphigoid.
Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function. Eotaxin-1 is a potent activator and chemoattractant of eosinophils (disease-fighting human white blood cells). Increased numbers of eosinophils are a feature of several diseases, including those of allergic origin (for example, asthma, rhinitis, inflammatory bowel diseases, and more severe conjunctivitis), and in many cases are believed to be the major cells affecting tissue damage. Eosinophil degranulation products have been shown to have significant toxic effects on tissues, and cytokines are known to be released by eosinophils to enhance the inflammatory cascade. Eotaxin-1 has a substantial role in the process by which eosinophils are recruited into tissues. It is also involved in eosinophil activation. By blocking eotaxin-1, one may be able to prevent or reduce tissue eosinophil accumulation and, as a result, prevent subsequent tissue injury.
Recently, bertilimumab has been investigated in a Phase II trial to treat newly diagnosed moderate-to-extensive BP. The trial targeted patients with BP and revealed good safety and efficacy results.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Bertilimumab Analytical Perspective by DelveInsight
This report provides a detailed market assessment of bertilimumab for bullous pemphigoid in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of bertilimumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions